Fate Therapeutics Stock Zacks
F ate therapeutics (fate) came out with a quarterly loss of $0.57 per share versus the zacks consensus estimate of a loss of $0.58. Want the latest recommendations from zacks investment research?
Zacks.com our research, your success
Fate therapeutics stock zacks. Shares of the company have surged 391.6% in the year. This compares to loss of $0.36 per share a. Price | fate therapeutics, inc.
Bitcoin, like the internet itself, could change everything Notably, fate therapeutics has a zacks rank #3 (hold). Fate therapeutics has a zacks rank of 3.
Do the numbers hold clues to what lies ahead for the stock? Our research shows that stocks rated zacks rank #1 (strong buy) and #2 (buy) and style scores of a or b outperform the market over the. 4, 2021 at 5:15 p.m.
(nasdaq:fate) to report $7.07 million in sales for the current quarter, according to zacks investment research. Fate therapeutics currently has a zacks rank of #2 (buy). Eight analysts have issued estimates for fate therapeutics' earnings, with estimates ranging from ($0.94) to ($0.41).
Fate therapeutics (fate) reports q3 loss, tops revenue estimates nov. It's no surprise fate therapeutics has a zacks rank #4 (sell). Eight analysts have issued estimates for fate therapeutics’ earnings.
Nov 4, 2021 5:15pm edt. (nasdaq:fate) to report earnings per share (eps) of ($0.66) for the current fiscal quarter, according to zacks investment research. You can see the complete list of today’s zacks #1 rank (strong buy) stocks here.
Fate therapeutics stock falls on trial data for lymphoma treatment. We expect a below average return from the stock in the next few months. The lowest sales estimate is $5.00 million and the highest is $16.10 million.
Et on zacks.com analysts estimate fate therapeutics (fate) to report a. Wall street analysts expect fate therapeutics, inc. (nasdaq:fate) has earned an average rating of buy from the twenty brokerages that are presently covering the company, marketbeat reports.
Fate therapeutics (fate) came out with a quarterly loss of $0.57 per share versus the zacks consensus estimate of a loss of $0.58. Notably, fate therapeutics has a zacks rank #3 (hold). Wall street analysts expect fate therapeutics, inc.
Shares have lost about 21% in that time frame, underperforming the s&p 500.will the. This suggests a possible upside of 92.7% from the stock's current price. Their forecasts range from $60.00 to $145.00.
On average, they expect fate therapeutics' share price to reach $107.83 in the next twelve months. Five research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Over the last 60 days, no analysts.
A month has gone by since the last earnings report for fate therapeutics (fate). Given that fate has a zacks rank #2 (buy) and an esp in positive territory, investors might want to consider this stock ahead of earnings. Get the latest broker recommendations from zacks investment research.
Get the latest interactive chart for fate therapeutics from zacks investment research
Posting Komentar untuk "Fate Therapeutics Stock Zacks"